Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disorder in which 20 % of patients are diagnosed in childhood.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune connective tissue disorder that manifests with a broad spectrum of clinical phenotypes. Approximately 20 % of SLE patients are diagnosed in childhood [1] . The average age of onset of pediatric SLE is between 12 and 14 years and rarely before the age of 5 years [2] . Childhood-onset SLE is associated with greater lifetime morbidity and mortality than adult-onset SLE [3] . Physicians have commonly relied on the American College of Rheumatology (ACR) Criteria for the classification of SLE. These criteria were preliminarily developed in 1971, revised in 1982, and updated in 1997 [4] . A person can be classified as having SLE if at least four of the 11 criteria are present. In order to address limitations of the ACR criteria, the Systemic Lupus International Collaborating Clinics (SLICC) developed the SLICC Classification Criteria in 2012, which exhibited a higher Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/11E6 F0607C5D0675. sensitivity and lower specificity than the ACR criteria [5] . The SLICC criteria include 11 clinical and six immunologic items. Classification criteria require four items with at least one clinical and one immunologic item, or biopsy-proven nephritis compatible with lupus in the presence of an ANA or anti-dsDNA [5] . The SLICC criteria has been validated in children, showing better sensitivity and fewer misclassifications than the ACR criteria [6] . Of note, these are no diagnostic criteria, and some patients need treatment despite not fitting classification criteria.
Children with SLE are at a significantly higher risk of disease damage than adults with SLE [7] . A multidisciplinary therapeutic approach is necessary in order to treat pediatric SLE (pSLE). In this review, we aim to provide and review the recommendations for the management of children with SLE. This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
Quality Indicators for pSLE
In 2013, an international consensus was reached for the first set of quality indicators for pSLE patients. The consensus resulted in 26 quality indicators for pSLE (Table 1) . Although there are similarities to quality indicators proposed for adult SLE, distinct pediatric concerns were incorporated, including high dose glucocorticoid therapy at diagnosis, antibody profile testing, ophthalmology screening, treatment of lupus nephritis, and monitoring for medication safety [3] .
Treatment of pSLE
Medical management of pSLE differs between providers, but will usually have the same principal approach. Most patients will require glucocorticoids and often immunosuppressive drugs, with the aim of reducing disease activity while also preventing long-term toxicities from medications. There are ongoing studies to develop treatment guidelines. Table 3 ) a 2. IF a patient has confirmed childhood-onset SLE, THEN the following laboratory studies should be obtained (see Table 3 ) infection, and hepatotoxicity, respectively [29] .
Glucocorticoids

Rituximab
An anti-CD20 monoclonal antibody, rituximab, targets B-cells and their ability for antibody production. Studies have shown that that rituximab is particularly effective in treating SLE-associated cytopenias [30] . In patients with severe SLE organ involvement, benefit has been shown in using rituximab and cyclophosphamide together [31] . Prior to initiating therapy with escape regulatory mechanisms and differentiate into autoantibody-secreting plasma cells [34] .
Belimumab has been shown to be effective in autoantibody-positive adult SLE patients with moderately active disease whose clinical manifestations are predominantly mucocutaneous and/or musculoskeletal and emerging data confirms that pSLE patients with similar characteristics also respond favorably to belimumab, in particular, suggesting a potential role for belimumab as a steroid-sparing agent [35] .
Another pathway developing for lupus treatment is the mTOR blockade with the use of rapamycin. This is currently being studied to treat refractory lupus in children. Rapamycin blocks T cell activation in patients with SLE with remarkable therapeutic efficacy since the activation of mTORC1 preceded disease flares and responded to therapeutic intervention with rapamycin [36] .
Other future therapies target IFN-regulated genes. Chronic activation of the innate immune system in SLE, including upregulated IFN-regulated genes (IFN signature), has led to the development of biologic agents targeting this cytokine in SLE [37] .
Barriers to Treatment
A multidisciplinary approach is needed to provide best practices in the care of pSLE patients. Social and psychological problems, mood changes and depression, disease complications, or drug-related issues are common in teenagers with chronic diseases such as lupus, and require special attention by psychologists and social workers [38] . Appropriately educating pSLE patients and involving them in their care plan is essential.
Pediatric patients with rheumatic diseases may not be sufficiently engaged in their medical care or unwilling to engage, and therefore lack understanding of the purposes of their medications [39] . Encouraging patients to develop self-care skills, especially as they transition to adult care, is important.
Non-adherence is associated with poorer health perceptions, self-esteem, mental health, family cohesion, and social functioning [40] . Psychosocial and educational interventions targeted at improving confidence, self-efficacy, disease-related knowledge, social support, and resolving insecurities regarding patients' capacity for self-management may alleviate psychosocial distress and improve adherence and health outcomes of adolescents and young adults with SLE [41] .
Transition of care is an important time in a pSLE patient's life. The successful transition from pediatric to adult care for patients with chronic conditions is predicated on the ability of the individual to achieve self-efficacy and disease self-management skills as well as the ability of the medical system to provide patient-centered care [42] . A recent study regarding transition of SLE patients showed that transfer of care from pediatric to adult providers was characterized by moderately high disease activity, prolonged time between the last pediatric and first adult provider appointments, and frequent gaps in care [42] .
Major challenges with transition of pSLE patients are loss of insurance and attachment to pediatric providers [43] . This supports the need for a structured transition process that helps prepare patients for the expectations of adult care. Continued follow-up studies are needed to solidify strategies that will be proven to be successful over a long period of time. 
CONCLUSIONS
